Iterum Therapeutics plc (ITRMF) Cash from Financing Activities (2018 - 2025)

Iterum Therapeutics has reported Cash from Financing Activities for 8 years, with the latest figure at $5.4 million in Q3 2025.

• On a quarterly basis, Cash from Financing Activities changed 0.04% year-over-year to $5.4 million in Q3 2025; TTM through Sep 2025 was $16.0 million, a 19.68% increase from a year earlier, with the FY2024 full-year figure at $26.7 million, up 2481.33% from the prior year.
• Cash from Financing Activities was $5.4 million for Q3 2025 at Iterum Therapeutics, up from $5.1 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $87.0 million in Q1 2021, with the low at -$8.4 million in Q1 2025.
• Average Cash from Financing Activities over 5 years is $6.5 million, with a median of $235000.0 recorded in 2023.
• The sharpest annual moves came in 2021 and 2024: Cash from Financing Activities plunged 313.04% in 2021, then soared 54200.0% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$1.6 million in 2021, then soared by 126.58% to $433000.0 in 2022, then jumped by 36.03% to $589000.0 in 2023, then surged by 2256.03% to $13.9 million in 2024, then slumped by 60.86% to $5.4 million in 2025.
• The last three Cash from Financing Activities figures came in at $5.4 million (Q3 2025), $5.1 million (Q2 2025), and -$8.4 million (Q1 2025), per Business Quant data.